Xeolas Pharmaceuticals has officially opened a 158,000-square-foot facility in Baldoyle, Dublin, marking a significant step in the Irish-owned company’s plans to expand pharmaceutical research, manufacturing and international supply. The development highlights the growing importance of specialist drug innovation within business news Ireland, particularly as companies seek to address unmet patient needs.
A new base for pharmaceutical growth
The Baldoyle site brings several key functions together under one roof, including research, formulation development, manufacturing and regulatory operations. Its scale and design are intended to support Xeolas as it advances medicines from early development through to commercial production.
The surrounding area also provides room for potential future expansion, giving the company a platform to respond to rising international demand for patient-focused treatments.
Founded in Ireland in 2007 by pharmacist and pharmaceutical executive Damien Flynn, Xeolas now employs more than 100 people. The company is active in 21 countries and has a development pipeline of more than 25 products, many of which are at an advanced stage.
Developing more patient-friendly medicines
Rather than focusing solely on entirely new medicines, Xeolas works with established active substances and existing clinical evidence to create improved formulations. This approach can help make treatments easier to use for patient groups whose needs may not be fully addressed by conventional drug-development models.
The company manages the full pharmaceutical value chain, including:
- Formulation and product development
- Clinical and regulatory work
- Manufacturing and quality operations
- Commercial supply for international markets
Its products are approved in major European markets and distributed internationally through commercial partners. Existing products include Pedippi, an oral omeprazole formulation developed for children, and Bonasol, a drinkable alendronic acid solution.
Read more
For further context on Ireland’s business environment, explore the latest Irish business updates and enterprise stories from Daily Digest.
What the opening means for Ireland
The new facility strengthens Ireland’s reputation as a centre for pharmaceutical innovation, advanced manufacturing and highly skilled employment. It also demonstrates how an Irish-owned company can build capabilities across research, regulation and production while serving international markets.
Enterprise Ireland’s support for companies with global ambitions remains central to this growth model. Leo McAdams, Head of Advanced Manufacturing, Construction and Lifesciences at Enterprise Ireland, said supporting Irish companies as they scale internationally is a key priority, with job creation and long-term competitiveness among the expected benefits.
For Xeolas, the facility is intended to give its scientific, clinical, regulatory and commercial teams greater capacity to move products from development to supply. That integrated structure may help the company progress its pipeline while maintaining a strong focus on practical patient outcomes.
Explore more
Readers following innovation, investment and company expansion can also discover Ireland business analysis and technology-sector coverage from Media Digest.
What comes next for Xeolas?
Xeolas is expected to use the Baldoyle site to support the continued development of its product pipeline and extend its presence in international markets. With more than 25 products in development and a growing global footprint, the company’s next phase will depend on successful regulatory progress, manufacturing scale-up and commercial partnerships.
Frequently asked questions
What has Xeolas opened in Baldoyle?
Xeolas has opened a 158,000-square-foot facility combining pharmaceutical research, development, manufacturing and regulatory capabilities.
How many people does Xeolas employ?
The Irish-owned company employs more than 100 people in Ireland.
Where does Xeolas operate?
Xeolas is currently present in 21 countries, with products approved in major European markets and supplied internationally through partners.
The opening represents an important milestone for Ireland’s pharmaceutical sector. By combining patient-focused formulation expertise with expanded manufacturing capacity, Xeolas is positioning itself for international growth while reinforcing the role of Irish companies in global medicine development. This is a notable example of business news Ireland with implications for innovation, skilled employment and the country’s wider life-sciences economy.
